Scientists zero in on how lung cancer spreads

December 24, 2014, Cancer Research UK
Normal cells (left) compared to when the cell ties are broken down (right). Credit: Vaughan et al. Cell Reports.

Cancer Research UK scientists have taken microscopic images revealing that the protein ties tethering cells together are severed in lung cancer cells - meaning they can break loose and spread, according to research published in Cell Reports today.

The researchers at the Cancer Research UK Manchester Institute discovered that the ties which lash together - controlled by a protein called TIAM1 - are chopped up when cell maintenance work goes wrong.

Healthy cells routinely scrap old cell parts so they can be broken down and used again. But this process spirals out of control in lung cancer cells, which scrap too many TIAM1 ties. (This happens because there is too much of a protein, called HUWE1, which is in charge of scrapping TIAM1).

Targeting this recycling process could stop lung cancer from spreading by keeping the cells stuck firmly together.

Lead researcher, Dr Angeliki Malliri, at the Cancer Research UK Manchester Institute at the University of Manchester, said: "This important research shows for the first time how sever ties with their neighbours and start to spread around the body, by hijacking the cells' and sending it into overdrive. Targeting this flaw could help stop lung cancer from spreading."

There are almost 43,500 new cases of in the UK each year. It is the most common cause of cancer deaths and kills more than 35,000 people in the UK each year.

Nell Barrie, Cancer Research UK's senior science information manager, said: "Lung cancer causes more than one in five of all cancer deaths in the UK and it's vital that we find effective new treatments to fight the disease and save more lives.

"Early-stage research like this is essential to find treatments which could one day block cancer spread - which would be a game changer. It's also crucial that we find ways to diagnose the disease earlier, when treatment is more likely to be successful and the is less likely to have spread."

The University of Manchester, including the Cancer Research UK Manchester Institute, joined forces with Cancer Research UK and The Christie NHS Foundation Trust to form the Manchester Cancer Research Centre, allowing doctors and scientists to work closely together to turn scientific advances into patient benefits sooner.

Explore further: Scientists trigger self-destruct switch in lung cancer cells

More information: Vaughan et al. HUWE1 ubiquitylates and degrades the Rac activator TIAM1 promoting cell-cell adhesion disassembly, migration and invasion. Cell Reports. DOI: 10.1016/j.celrep.2014.12.012

Related Stories

Scientists trigger self-destruct switch in lung cancer cells

October 31, 2014
Cancer Research UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells - paving the way for new treatments, according to research that will be presented at the National ...

Scientists uncover vast numbers of DNA 'blind spots' that may hide cancer-causing mistakes

November 14, 2014
Cancer Research UK scientists have found more than 400 'blind spots' in DNA which could hide cancer-causing gene faults, according to research published today in Cancer Research.

Scientists pinpoint a new line of defence used by cancer cells

December 8, 2014
Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications today.

Piggy-backing cells hold clue to skin cancer growth (w/ Video)

July 24, 2014
Skin Cancer cells work together to spread further and faster, according to a new study published in Cell Reports. The discovery could lead to new drugs to tackle melanoma, the most deadly form of skin cancer.

More evidence for impact of lung cancer targeted therapy from practice-changing trial

December 4, 2014
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

Immunotherapy could stop resistance to radiotherapy

October 1, 2014
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, according to a study published in Cancer Research today.

Recommended for you

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.